Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Valent Technologies, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT04337177
- Locations
- 🇺🇸
Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸Sarah Cannon Research Institute, Pediatric Hematology & Oncology, Nashville, Tennessee, United States
🇺🇸Duke University Children's Hospital and Health Center, Durham, North Carolina, United States
© Copyright 2024. All Rights Reserved by MedPath